Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03869008 · ClinicalTrials.gov registry record · NA
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
A NA study, sponsored by University of Toledo Health Science Campus.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT03869008 is a NA study that was terminated before completion, run by University of Toledo Health Science Campus. The registered enrollment target is 6 participants.
The verdict
NCT03869008, a NA study, was terminated before completion, sponsored by University of Toledo Health Science Campus.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of vasospasm of the digital arteries in addition to significant impairment of quality of life. It is well known that cold exposure precipitates episodes of RP, but the mechanism for cold sensitivity is not known, and treatment of RP is not satisfactory to the patients and their physicians. The goal in this study is to test the possibility that non invasive vagus nerve stimulation (nVNS) with gammaCore which is already approved by the FDA for headaches and migraines may be an effective and well tolerated therapy for Raynaud's Phenomenon.
Interventions
- DEVICE Sham Device
- DEVICE gammaCore Sapphire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2020-02-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03869008
The ClinicalTrials.gov registry entry for NCT03869008 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Toledo Health Science Campus, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Device is the first listed.
NCT03869008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03869008 about?
NCT03869008 is a clinical study titled "Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.". Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of vasospasm of the digital arteries in addition to significant impairment of qua...
What is the current status of trial NCT03869008?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2019-04-30. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03869008?
The interventions under investigation include: Sham Device (DEVICE), gammaCore Sapphire (DEVICE).
Who is sponsoring clinical trial NCT03869008?
This trial is sponsored by University of Toledo Health Science Campus, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.